{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:22:17Z","timestamp":1792718537495,"version":"4.5.0"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002590","name":"American Lung Association","doi-asserted-by":"publisher","award":["821321"],"award-info":[{"award-number":["821321"]}],"id":[{"id":"10.13039\/100002590","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["RA210084"],"award-info":[{"award-number":["RA210084"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["R01 HL177140"],"award-info":[{"award-number":["R01 HL177140"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["RSG-19-166-01-TB"],"award-info":[{"award-number":["RSG-19-166-01-TB"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["R01 GM144890"],"award-info":[{"award-number":["R01 GM144890"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["R21 CA259706"],"award-info":[{"award-number":["R21 CA259706"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["R01 CA258614"],"award-info":[{"award-number":["R01 CA258614"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005188","name":"Tobacco-Related Disease Research Program","doi-asserted-by":"publisher","award":["R01CA244341"],"award-info":[{"award-number":["R01CA244341"]}],"id":[{"id":"10.13039\/100005188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005188","name":"Tobacco-Related Disease Research Program","doi-asserted-by":"publisher","award":["T33IR6461"],"award-info":[{"award-number":["T33IR6461"]}],"id":[{"id":"10.13039\/100005188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society Inc","doi-asserted-by":"publisher","award":["IRG-21-142-16"],"award-info":[{"award-number":["IRG-21-142-16"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030442","name":"Anna Fuller Fund","doi-asserted-by":"publisher","award":["21005962"],"award-info":[{"award-number":["21005962"]}],"id":[{"id":"10.13039\/100030442","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP220145"],"award-info":[{"award-number":["RP220145"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA229275"],"award-info":[{"award-number":["R01CA229275"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA265827"],"award-info":[{"award-number":["R01CA265827"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA160417"],"award-info":[{"award-number":["R01CA160417"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA211070"],"award-info":[{"award-number":["R01CA211070"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21CA259243"],"award-info":[{"award-number":["R21CA259243"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.canlet.2025.218194","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T07:51:02Z","timestamp":1764661862000},"page":"218194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["SRC at the crossroads of KRAS inhibitor resistance: Mechanisms and therapeutic opportunities"],"prefix":"10.1016","volume":"639","author":[{"given":"Hui","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huocong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxia","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert J.","family":"Zeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth D.","family":"Westover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2025.218194_bib1","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.218194_bib2","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS(G12C) inhibition with Sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218194_bib3","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.adm8684","article-title":"Targeting cancer with small-molecule pan-KRAS degraders","volume":"385","author":"Popow","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.canlet.2025.218194_bib4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","article-title":"Pan-KRAS inhibitor disables oncogenic signalling and tumour growth","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.218194_bib5","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1158\/2159-8290.CD-24-0840","article-title":"Discovery of BBO-8520, a first-in-class direct and covalent dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C","volume":"15","author":"Maciag","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2025.218194_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.seminoncol.2025.152399","article-title":"Application prospects of tumor vaccines for pancreatic cancer: from TAAs to TSAs and combination strategies","volume":"52","author":"Lu","year":"2025","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.canlet.2025.218194_bib7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","article-title":"Diverse alterations associated with resistance to KRAS(G12C) inhibition","volume":"599","author":"Zhao","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.218194_bib8","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","article-title":"Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition","volume":"26","author":"Ryan","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218194_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216692","article-title":"AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells","volume":"587","author":"Morimoto","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.218194_bib10","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1016\/j.celrep.2020.03.021","article-title":"Defining and targeting adaptations to oncogenic KRAS(G12C) inhibition using quantitative temporal proteomics","volume":"30","author":"Santana-Codina","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2025.218194_bib11","article-title":"Decoding the proteostasis network in resistance to KRAS inhibitors","volume":"4","author":"Song","year":"2023","journal-title":"Innovation"},{"key":"10.1016\/j.canlet.2025.218194_bib12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1126\/science.aad6204","article-title":"Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism","volume":"351","author":"Lito","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.canlet.2025.218194_bib13","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1158\/1078-0432.CCR-18-0368","article-title":"KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition","volume":"25","author":"Misale","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218194_bib14","doi-asserted-by":"crossref","first-page":"eadq4274","DOI":"10.1126\/sciadv.adq4274","article-title":"SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition","volume":"10","author":"Song","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2025.218194_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.178535","article-title":"YAP\/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5\/mTOR axis","volume":"9","author":"Yang","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2025.218194_bib16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1084\/jem.13.4.397","article-title":"A sarcoma of the fowl transmissible by an agent separable from the tumor cells","volume":"13","author":"Rous","year":"1911","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2025.218194_bib17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/260170a0","article-title":"DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA","volume":"260","author":"Stehelin","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.218194_bib18","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/269346a0","article-title":"Identification of a transformation-specific antigen induced by an avian sarcoma virus","volume":"269","author":"Brugge","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.218194_bib19","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1073\/pnas.77.3.1311","article-title":"Transforming gene product of rous sarcoma virus phosphorylates tyrosine","volume":"77","author":"Hunter","year":"1980","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2025.218194_bib20","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/0092-8674(83)90073-9","article-title":"Structure and sequence of the cellular gene homologous to the RSV src gene and the mechanism for generating the transforming virus","volume":"32","author":"Takeya","year":"1983","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.218194_bib21","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/385595a0","article-title":"Three-dimensional structure of the tyrosine kinase c-Src","volume":"385","author":"Xu","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.218194_bib22","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1038\/sj.onc.1203912","article-title":"Role of Src expression and activation in human cancer","volume":"19","author":"Irby","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.218194_bib23","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2025.218194_bib24","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.218194_bib25","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218194_bib26","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrm2957","article-title":"Cell adhesion: integrating cytoskeletal dynamics and cellular tension","volume":"11","author":"Parsons","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2025.218194_bib27","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/ncb2756","article-title":"Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts","volume":"15","author":"Calvo","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2025.218194_bib28","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1021\/acs.jmedchem.9b01502","article-title":"Structure-Based design of a potent and selective covalent inhibitor for SRC kinase that targets a P-Loop cysteine","volume":"63","author":"Du","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2025.218194_bib29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ccell.2014.11.006","article-title":"Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma","volume":"27","author":"Girotti","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2025.218194_bib30","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1634\/theoncologist.2014-0228","article-title":"A phase I\/II study combining erlotinib and dasatinib for non-small cell lung cancer","volume":"19","author":"Gold","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2025.218194_bib31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1021\/acschembio.3c00548","article-title":"Selective and potent PROTAC degraders of c-Src kinase","volume":"19","author":"Mao","year":"2024","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.canlet.2025.218194_bib32","doi-asserted-by":"crossref","first-page":"6548","DOI":"10.1038\/s41467-023-41890-7","article-title":"An allosteric switch between the activation loop and a c-terminal palindromic phospho-motif controls c-Src function","volume":"14","author":"Cuesta-Hern\u00e1ndez","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.218194_bib33","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/s41388-021-02092-x","article-title":"Regulation of Src tumor activity by its N-terminal intrinsically disordered region","volume":"41","author":"Aponte","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.218194_bib34","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1073\/pnas.96.4.1415","article-title":"Mechanism of biological synergy between cellular Src and epidermal growth factor receptor","volume":"96","author":"Tice","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2025.218194_bib35","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1128\/MCB.00246-10","article-title":"Myristoylation and membrane binding regulate c-Src stability and kinase activity","volume":"30","author":"Patwardhan","year":"2010","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2025.218194_bib36","doi-asserted-by":"crossref","first-page":"24249","DOI":"10.1016\/S0021-9258(18)54220-4","article-title":"CSK: a protein-tyrosine kinase involved in regulation of src family kinases","volume":"266","author":"Okada","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2025.218194_bib37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1073\/pnas.91.1.83","article-title":"Involvement of pp60c-src with two major signaling pathways in human breast cancer","volume":"91","author":"Luttrell","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2025.218194_bib38","doi-asserted-by":"crossref","first-page":"8959","DOI":"10.1074\/jbc.271.15.8959","article-title":"Direct binding of C-terminal region of p130Cas to SH2 and SH3 domains of Src kinase","volume":"271","author":"Nakamoto","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2025.218194_bib39","doi-asserted-by":"crossref","first-page":"9021","DOI":"10.1073\/pnas.96.16.9021","article-title":"Focal adhesion kinase promotes phospholipase C-gamma1 activity","volume":"96","author":"Zhang","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2025.218194_bib40","doi-asserted-by":"crossref","first-page":"17749","DOI":"10.1016\/S0021-9258(17)32504-8","article-title":"Raf-1 interacts with Fyn and Src in a non-phosphotyrosine-dependent manner","volume":"269","author":"Cleghon","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2025.218194_bib41","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1074\/jbc.273.1.577","article-title":"SH2- and SH3-mediated interactions between focal adhesion kinase and Src","volume":"273","author":"Thomas","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2025.218194_bib42","doi-asserted-by":"crossref","first-page":"12487","DOI":"10.1074\/jbc.C100760200","article-title":"v-Src SH3-enhanced interaction with focal adhesion kinase at beta 1 integrin-containing invadopodia promotes cell invasion","volume":"277","author":"Hauck","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2025.218194_bib43","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1126\/science.8128248","article-title":"Activation of phosphatidylinositol-3' kinase by Src-family kinase SH3 binding to the p85 subunit","volume":"263","author":"Pleiman","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.canlet.2025.218194_bib44","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1126\/science.7541555","article-title":"Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein","volume":"269","author":"Yu","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.canlet.2025.218194_bib45","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1038\/onc.2010.589","article-title":"Oncogenic Ras\/Src cooperativity in pancreatic neoplasia","volume":"30","author":"Shields","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.218194_bib46","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13045-019-0837-z","article-title":"Aspartate \u03b2-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway","volume":"12","author":"Ogawa","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2025.218194_bib47","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.274.51.36734","article-title":"Regulation of E-cadherin\/Catenin association by tyrosine phosphorylation","volume":"274","author":"Roura","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2025.218194_bib48","doi-asserted-by":"crossref","first-page":"8335","DOI":"10.1074\/jbc.274.12.8335","article-title":"c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function","volume":"274","author":"Biscardi","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2025.218194_bib49","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41418-018-0114-7","article-title":"Integrin \u03b16\u03b24-Src-AKT signaling induces cellular senescence by counteracting apoptosis in irradiated tumor cells and tissues","volume":"26","author":"Jung","year":"2019","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2025.218194_bib50","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1158\/0008-5472.CAN-17-0391","article-title":"Src inhibits the Hippo tumor suppressor pathway through tyrosine phosphorylation of Lats1","volume":"77","author":"Si","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.218194_bib51","doi-asserted-by":"crossref","first-page":"25113","DOI":"10.18632\/oncotarget.7159","article-title":"Src drives the Warburg effect and therapy resistance by inactivating pyruvate dehydrogenase through tyrosine-289 phosphorylation","volume":"7","author":"Jin","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2025.218194_bib52","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.celrep.2020.03.005","article-title":"c-Src promotes tumorigenesis and tumor progression by activating PFKFB3","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2025.218194_bib53","article-title":"Tricin selectively combats KRAS-mutant non-small cell lung cancer by inhibiting the PDGF-BB-induced SRC\/MAPK\/AP-1\/PD-L1 signaling pathway and potentiating the antitumor effect of an anti-PD-1 antibody","volume":"16","author":"Li","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2025.218194_bib54","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.ATV.18.2.227","article-title":"Shear stress activates p60src-Ras-MAPK signaling pathways in vascular endothelial cells","volume":"18","author":"Jalali","year":"1998","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.canlet.2025.218194_bib55","doi-asserted-by":"crossref","first-page":"22892","DOI":"10.1074\/jbc.273.36.22892","article-title":"Involvement of protein kinase C and Src family tyrosine kinase in Galphaq\/11-induced activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase","volume":"273","author":"Nagao","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2025.218194_bib56","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ccell.2018.10.001","article-title":"KRAS suppression-induced degradation of MYC is antagonized by a MEK5-ERK5 compensatory mechanism","volume":"34","author":"Vaseva","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2025.218194_bib57","doi-asserted-by":"crossref","first-page":"E3855","DOI":"10.1073\/pnas.1510733112","article-title":"EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function","volume":"112","author":"Phuchareon","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2025.218194_bib58","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41416-022-02032-w","article-title":"PAK and PI3K pathway activation confers resistance to KRAS(G12C) inhibitor sotorasib","volume":"128","author":"Chan","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2025.218194_bib59","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1074\/jbc.RA118.004364","article-title":"SRC tyrosine kinase activates the YAP\/TAZ axis and thereby drives tumor growth and metastasis","volume":"294","author":"Lamar","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2025.218194_bib60","article-title":"Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers","volume":"6","author":"Theardy","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2025.218194_bib61","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1158\/1541-7786.MCR-19-0741","article-title":"Combined Src\/EGFR inhibition targets STAT3 signaling and induces stromal remodeling to improve survival in pancreatic cancer","volume":"18","author":"Dosch","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218194_bib62","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13072-019-0297-2","article-title":"MEK inhibition remodels the active chromatin landscape and induces SOX10 genomic recruitment in BRAF(V600E) mutant melanoma cells","volume":"12","author":"Fufa","year":"2019","journal-title":"Epigenetics Chromatin"},{"key":"10.1016\/j.canlet.2025.218194_bib63","doi-asserted-by":"crossref","first-page":"7253","DOI":"10.18632\/oncotarget.6635","article-title":"A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer","volume":"7","author":"Paladino","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2025.218194_bib64","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1038\/s41467-021-26993-3","article-title":"Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein","volume":"12","author":"Tripathi","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.218194_bib65","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/s43018-024-00847-5","article-title":"The pro-oncogenic noncanonical activity of a RAS\u2022GTP:RanGAP1 complex facilitates nuclear protein export","volume":"5","author":"Tripathi","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.canlet.2025.218194_bib66","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1038\/s41388-022-02487-4","article-title":"Src: coordinating metabolism in cancer","volume":"41","author":"Pelaz","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.218194_bib67","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12964-022-00955-8","article-title":"Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo","volume":"20","author":"Zhang","year":"2022","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.canlet.2025.218194_bib68","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/ar.24269","article-title":"Bosutinib acts as a tumor inhibitor via downregulating Src\/NF-kappaB\/Survivin expression in HeLa cells","volume":"302","author":"Yu","year":"2019","journal-title":"Anat. Rec."},{"key":"10.1016\/j.canlet.2025.218194_bib69","doi-asserted-by":"crossref","first-page":"eabl7895","DOI":"10.1126\/scitranslmed.abl7895","article-title":"Targeting Src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models","volume":"15","author":"Su","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2025.218194_bib70","article-title":"Focal Adhesion Kinase (FAK) inhibition synergizes with KRAS G12C inhibitors in treating cancer through the regulation of the FAK-YAP signaling","volume":"8","author":"Zhang","year":"2021","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.canlet.2025.218194_bib71","article-title":"Src-FAK signaling mediates interleukin 6-Induced HCT116 colorectal cancer epithelial-mesenchymal transition","volume":"24","author":"Huang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2025.218194_bib72","doi-asserted-by":"crossref","first-page":"392","DOI":"10.31083\/j.fbl2911392","article-title":"Signal transduction mechanisms of focal adhesions: src and FAK-Mediated cell response","volume":"29","author":"Katoh","year":"2024","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"10.1016\/j.canlet.2025.218194_bib73","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1083\/jcb.200212114","article-title":"Differential regulation of cell motility and invasion by FAK","volume":"160","author":"Hsia","year":"2003","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.canlet.2025.218194_bib74","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41586-020-03046-1","article-title":"Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis","volume":"589","author":"Pastushenko","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.218194_bib75","first-page":"15","article-title":"The Hippo pathway effectors YAP\/TAZ-TEAD oncoproteins as emerging therapeutic targets in the Tumor microenvironment","author":"Mokhtari","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2025.218194_bib76","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41556-020-0560-6","article-title":"Epigenetic silencing of the ubiquitin ligase subunit FBXL7 impairs c-SRC degradation and promotes epithelial-to-mesenchymal transition and metastasis","volume":"22","author":"Moro","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2025.218194_bib77","article-title":"Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models","volume":"135","author":"Li","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2025.218194_bib78","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2141978","article-title":"Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy","volume":"11","author":"Song","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2025.218194_bib79","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1111\/febs.15011","article-title":"Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy","volume":"286","author":"Parkin","year":"2019","journal-title":"FEBS J."},{"key":"10.1016\/j.canlet.2025.218194_bib80","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001496","article-title":"SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation","volume":"9","author":"Redin","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218194_bib81","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1158\/0008-5472.CAN-24-2772","article-title":"Dasatinib remodels the tumor microenvironment and sensitizes small cell lung cancer to immunotherapy","volume":"85","author":"Redin","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.218194_bib82","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1600-065X.2008.00745.x","article-title":"T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance","volume":"228","author":"Salmond","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2025.218194_bib83","article-title":"Unraveling the CDK9\/PP2A\/ERK network in transcriptional pause release and complement activation in KRAS-mutant cancers","volume":"11","author":"Wang","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.canlet.2025.218194_bib84","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.218194_bib85","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41388-023-02701-x","article-title":"Functional roles of SRC signaling in pancreatic cancer: recent insights provide novel therapeutic opportunities","volume":"42","author":"Poh","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.218194_bib86","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nm.4123","article-title":"Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy","volume":"22","author":"Jiang","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.218194_bib87","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1038\/s41467-023-39571-6","article-title":"Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer","volume":"14","author":"Zhou","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.218194_bib88","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1038\/s41388-021-01752-2","article-title":"A molecular subtype of colorectal cancers initiates independently of epidermal growth factor receptor and has an accelerated growth rate mediated by IL10-dependent anergy","volume":"40","author":"Mantilla-Rojas","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.218194_bib89","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1021\/ja208518u","article-title":"Cell-Based proteome profiling of potential dasatinib targets by use of affinity-based probes","volume":"134","author":"Shi","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.canlet.2025.218194_bib90","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.annonc.2020.10.483","article-title":"The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers","volume":"32","author":"Saturno","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.218194_bib91","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3389\/fmolb.2020.00081","article-title":"Structure and characterization of a covalent inhibitor of src kinase","volume":"7","author":"Gurbani","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.canlet.2025.218194_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108185","article-title":"Identification of a novel Src inhibitor K882 derived from quinazoline-based stilbenes with anti-NSCLC effect","volume":"156","author":"Ma","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.canlet.2025.218194_bib93","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1053\/j.gastro.2010.03.034","article-title":"Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma","volume":"139","author":"Morton","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2025.218194_bib94","first-page":"12","article-title":"Src family kinases as therapeutic targets in advanced solid tumors: what we have learned so far","author":"Martellucci","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2025.218194_bib95","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1158\/1535-7163.MCT-21-0964","article-title":"Opposite effects of src family kinases on YAP and ERK activation in pancreatic cancer cells: implications for targeted therapy","volume":"21","author":"Sinnett-Smith","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2025.218194_bib96","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41392-023-01501-9","article-title":"Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets","volume":"8","author":"Di","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2025.218194_bib97","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","article-title":"Pancreatic cancer stroma: an update on therapeutic targeting strategies","volume":"17","author":"Hosein","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2025.218194_bib98","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","article-title":"Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties","volume":"158","author":"Hegedus","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.canlet.2025.218194_bib99","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2018.05.013","article-title":"Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity","volume":"99","author":"Rao","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2025.218194_bib100","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/1878-0261.13151","article-title":"Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment","volume":"16","author":"Dawson","year":"2022","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.canlet.2025.218194_bib101","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/1078-0432.CCR-10-1670","article-title":"Combined blockade of src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-Mediated resistance of inhibition of pancreatic tumor growth","volume":"17","author":"Nagaraj","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218194_bib102","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/onc.2010.430","article-title":"Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab","volume":"30","author":"Dunn","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.218194_bib103","first-page":"17","article-title":"Synergistic inhibition of drug resistant KRAS mutant non-small cell lung cancer by Co-Targeting AXL and SRC","author":"Mukherjee","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2025.218194_bib104","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccr.2010.04.026","article-title":"Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors","volume":"17","author":"Carretero","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2025.218194_bib105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010514","article-title":"Specific inhibitor to KRAS(G12C) induces tumor-specific immunity and synergizes with oncolytic virus for enhanced cancer immunotherapy","volume":"13","author":"Zhu","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218194_bib106","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.annonc.2024.11.014","article-title":"Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRAS(G12C) inhibitors","volume":"36","author":"Di Federico","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.218194_bib107","doi-asserted-by":"crossref","first-page":"148","DOI":"10.21037\/tlcr.2017.03.06","article-title":"Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation","volume":"6","author":"Schoenhals","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.canlet.2025.218194_bib108","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.7150\/thno.48865","article-title":"Development of the phenylpyrazolo[3,4-d]pyrimidine-based, insulin-like growth factor receptor\/Src\/AXL-targeting small molecule kinase inhibitor","volume":"11","author":"Lee","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2025.218194_bib109","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12943-018-0802-4","article-title":"Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R\/Src inhibitor as a novel anticancer agent with minimal toxicity","volume":"17","author":"Lee","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2025.218194_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101335","article-title":"The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer","volume":"297","author":"Diehl","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2025.218194_bib111","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41388-019-0985-1","article-title":"Rho guanine nucleotide exchange factor ARHGEF10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma","volume":"39","author":"Joseph","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.218194_bib112","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/cas.13929","article-title":"Preclinical pharmacodynamic evaluation of a new Src\/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma","volume":"110","author":"Yang","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2025.218194_bib113","first-page":"240","article-title":"A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF(V600E) colorectal tumors","volume":"4","author":"Ruiz-Saenz","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.canlet.2025.218194_bib114","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s43018-021-00325-2","article-title":"Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer","volume":"3","author":"Gavert","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.canlet.2025.218194_bib115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0281063","article-title":"Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo","volume":"18","author":"Fan","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2025.218194_bib116","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.clbc.2011.03.021","article-title":"Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer","volume":"11","author":"Gucalp","year":"2011","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.canlet.2025.218194_bib117","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40262-020-00872-4","article-title":"Clinical pharmacokinetics and pharmacodynamics of dasatinib","volume":"59","author":"Lev\u00eaque","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.canlet.2025.218194_bib118","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1158\/1078-0432.CCR-16-3138","article-title":"Dual inhibition of EGFR and c-Src by cetuximab and dasatinib combined with FOLFOX chemotherapy in patients with metastatic colorectal cancer","volume":"23","author":"Parseghian","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.218194_bib119","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/bloodadvances.2016003889","article-title":"The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia","volume":"1","author":"Fox","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.canlet.2025.218194_bib120","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1200\/JCO.2010.30.5474","article-title":"Phase II Study of dasatinib in patients with advanced Non\u2013small-cell lung cancer","volume":"28","author":"Johnson","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218194_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1380584","article-title":"KRAS G12C inhibitor combination therapies: current evidence and challenge","volume":"14","author":"Miyashita","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2025.218194_bib122","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.2147\/DDDT.S521260","article-title":"Dasatinib dose optimization based on therapeutic drug monitoring in patients with chronic-phase chronic myeloid leukemia","volume":"19","author":"Cheng","year":"2025","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.canlet.2025.218194_bib123","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3168","article-title":"A phase 1, first-in-human study of IK-930, an oral TEAD inhibitor targeting the Hippo pathway in subjects with advanced solid tumors","volume":"40","author":"Tolcher","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.218194_bib124","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1164\/rccm.201807-1292OC","article-title":"YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib","volume":"200","author":"Garmendia","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.canlet.2025.218194_bib125","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1172\/JCI37127","article-title":"Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions","volume":"119","author":"Sos","year":"2009","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2025.218194_bib126","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12885-022-09344-3","article-title":"An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy","volume":"22","author":"Yang","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2025.218194_bib127","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nature04296","article-title":"Oncogenic pathway signatures in human cancers as a guide to targeted therapies","volume":"439","author":"Bild","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.218194_bib128","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/0008-5472.CAN-06-3633","article-title":"Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection","volume":"67","author":"Huang","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.218194_bib129","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2147\/DDDT.S80207","article-title":"The role of dasatinib in the management of chronic myeloid leukemia","volume":"9","author":"Chen","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.canlet.2025.218194_bib130","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13853","article-title":"Phase II study of 5-Fluorouracil, oxaliplatin plus dasatinib (FOLFOX-D) in first-line metastatic pancreatic adenocarcinoma","volume":"26","author":"George","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2025.218194_bib131","article-title":"Phase 1 clinical trial of trametinib and ponatinib in patients with NSCLC harboring KRAS mutations","volume":"3","author":"Arbour","year":"2022","journal-title":"JTO Clin. Res. Rep."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525007669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525007669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:37:20Z","timestamp":1792096640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525007669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":131,"alternative-id":["S0304383525007669"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218194","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SRC at the crossroads of KRAS inhibitor resistance: Mechanisms and therapeutic opportunities","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218194","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218194"}}